Principal Investigator
Gerald Soff
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20240403
Clinical Trial Summary
A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND
REGN7508, MONOCLONAL ANTIBODIES AGAINST FACTOR XI FOR
PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS
WITH A PERIPHERALLY INSERTED CENTRAL CATHETER
(ROXI-CATH)
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Leukemia
Contact Information
Phone Number
305-243-2647